Look under a pharma executive's bed, and you'll find monsters. What do those monsters look like, though? Accenture talked to C-suite executives at the world's biggest drugmakers and found that some of yesteryear's scary beings have moved on, leaving others to take front and center.
Pfizer is recalling two lots of its 40 mg/ mL, 1 mL single-dose vials of its anti inflammatory product Depo-Medrol.
Pfizer may not get a great shot at buying AstraZeneca this fall--but it's preparing to give it a try. Meanwhile, Bloomberg reports, the U.S.-based drug giant is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.
When it comes to manufacturing, Big Pharma prefers traditional plants to living plants. While drugs manufactured from plants like tobacco have been in the news because several makers of Ebola drug candidates are using the process, the method has not been embraced by any of the major players.
As expected, Pfizer has submitted an early FDA application for palbociclib, beating a quick path to market with a breakthrough breast cancer treatment that could peak at nearly $3 billion a year.
Forget tax-advantaged Irish drugmakers. It may be a good time to take over an antibiotics maker on the cheap--and analysts have just the antibiotics maker in mind.
The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.
Pfizer and 23andMe have teamed up to identify genetic factors linked to inflammatory bowel disease. And with 23andMe trumpeting the fact that people can participate without leaving their homes, the study represents a continuation of Pfizer's interest in virtual trials.
Pfizer and Novartis are in a dead heat to become the first vaccinemaker to roll out a meningitis B vaccine for the U.S. market. But the New York pharma giant just became the first of the two to snag a decision date from the FDA, which says it will have an answer on Pfizer's candidate within the next 6 months.
Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. And once payer coverage kicks in, that's a nod that could be worth $2 billion for Pfizer, analysts say--with Merck's Pneumovax getting a boost, too.